BioSpace News Archive

Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it will report second quarter financial results after the Nasdaq market closes on Monday, August 3, 2020

Osmotica Pharmaceuticals plc, a fully integrated biopharmaceutical company, announced the commencement of a proposed public offering of 5,000,000 ordinary shares.

As COVID-19 surges in border states, the Association of American Physicians and Surgeons (AAPS) calls on governors to consider the approach used for HIV/AIDS instead of more lockdowns.

XPro1595 reduces neuroinflammation by 40.6% in a brain fiber pathway important for learning and memory

Galera Therapeutics, Inc. (Nasdaq: GRTX), today announced that it has completed patient enrollment in its pilot Phase 1b/2a safety and anti-cancer efficacy clinical trial of avasopasem manganese (GC4419) in combination with stereotactic body radiation therapy (SBRT) in patients with locally advanced pancreatic cancer (LAPC).

Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced preliminary financial and operating results for its first fiscal quarter ended June 30, 2020

Invacare Corporation (“Invacare”)(NYSE:IVC) will participate on Tuesday, July 14, 2020 in the 20th Annual CJS Securities New Ideas Summer Conference where the company’s management will provide a business update and share certain expected preliminary financial results for the second quarter ended June 30, 2020.

XS Financial Inc., (“XS Financial”, “XS” or the “Company”) (CSE:XSF) (OTCQB: XSHLF), a specialty finance company engaged in equipment leasing in the United States, announced today that it has closed the acquisition of a California Lenders License (‘CFL”), through the purchase of a local entity (the “Target Company”), in California as previously announced (see press release dated January 27, 2020)

Helix, the leading population genomics company, today announced a partnership with San Diego County to make COVID-19 testing accessible across the County to those who need it most.

Revitope Oncology Inc (“Revitope Oncology”)., a biotechnology company advancing a new class of precision cancer immunotherapies, its wholly-owned subsidiary Revitope Limited (Revitope Limited, together with Revitope Oncology, “Revitope”) and Junshi Biosciences (1877.HK, 688180.SH), a leading innovation–driven biopharmaceutical company dedicated to the discovery,